Reported 1 day ago
Merck (MRK) closed at $86.32, up 1.8% from the previous day, outpacing the gains of the S&P 500 and Dow. The pharmaceutical company has gained 4.02% over the last month, exceeding the Medical sector's performance. As Merck prepares to release its earnings report on October 30, 2025, expectations are for an EPS of $2.36 and revenues of $17.06 billion. The stock's current valuation shows a Forward P/E ratio of 9.5, compared to the industry's 14.56, suggesting it is undervalued. Overall, investors should be mindful of changing analyst forecasts and Merck's strong position within the Large Cap Pharmaceuticals industry.
Source: YAHOO